CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55

Benzinga Newsdesk www.benzinga.com Positive 92.2%

Neg 0% Neu 0% Pos 92.2%

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $42 to $55.